Bio
I was attracted to working at ICON as I thought it would be a great opportunity to work with a dynamic group of well-respected individuals. Coming from the pharma industry, I was already familiar with the positive reputation of the Health Economics team within the ICO division, as well as that of ICON as a whole.
After graduating with a Bachelor of Arts in Economics, I did a PhD in Health Economics before completing an MBA at London Business School. With 16 years of experience under my belt, including academia, consulting and pharma, with my most recent position, prior to joining ICON, being at Astellas Europe, where I was responsible for developing Health Economics and Market Access plans, and managing projects, for both pre- and post-launch products to ensure successful reimbursement and access.
I now head up the US practice of Health Economics and Epidemiology at ICON, having been with the company since 2011. Although I joined the company as a Lead Health Economist, I was promoted to a Director position 18 months later before becoming Principal heading up the US practice at the start of 2015. Come January 2016, I’ll be NA Head of Health Economics.
My favourite thing about working here is the team of people I work with. They are such a bright, dedicated group of people and working with them makes my job really exciting and fulfilling. The company culture is also another perk of working here. Everyone is committed to delivering the best possible end product and there’s a great family culture. I also like knowing that what we do has a positive impact on patients’ lives.
Someone who is committed to delivering high quality work would be the perfect fit at ICON. You can make a real difference here if you’re an individual who is not afraid to work and deliver as a team.
Latest jobs
Life at ICON
.png)
Teaser label
Inside ICONContent type
BlogsPublish date
05/08/2025
Summary
Standing Strong on Ovarian Cancer Day: ICON's Commitment to Advancing Care Ovarian cancer remains one of the most challenging gynaecologic malignancies, both in terms of detection and treatmen
.png)
Teaser label
IndustryContent type
BlogsPublish date
05/07/2025
Summary
Patient Centricity in Clinical Research: What it is and Why it Matters In the past, clinical research was designed around the needs of sponsors, researchers, and regulatory bodies. Patients were of
.png)
Teaser label
IndustryContent type
BlogsPublish date
05/05/2025
Summary
Navigating Regulatory Landscapes: Comparing FDA, EMA, & MHRA in Clinical Trials In clinical research, no matter how promising a new therapy may be, it will go nowhere without regulatory appro
Recently viewed jobs